Physician profile
Daniel Mcelroy
NPI 1104311844
$2,582.14
in general payments reported to CMS, 2019-2025
26 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $521 · 2022: $824 · 2023: $579 · 2024: $352 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,027 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,027.28 |
| Education | $209.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $606.58 | 2021-2023 | |
| Harmony Biosciences LLC | $460.99 | 2023-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $293.93 | 2021-2025 | |
| Abbvie INC. | $132.85 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $131.39 | 2022 | |
| Gilead Sciences, INC. | $125.00 | 2023 | Epclusa |
| Calliditas Therapeutics US INC. | $110.81 | 2022-2023 | Tarpeyo |
| Fresenius USA Marketing, INC. | $68.75 | 2022-2023 | Korsuva, Velphoro |
| Alnylam Pharmaceuticals INC. | $65.65 | 2021-2023 | Givlaari |
| Glaxosmithkline, LLC. | $62.35 | 2022-2023 | Benlysta |
| Horizon Therapeutics Plc | $62.13 | 2022-2023 | Krystexxa |
| Inspire Medical Systems, INC. | $54.22 | 2024-2025 | Inspire |
| Lilly USA, LLC | $53.08 | 2021-2025 | Zepbound |
| Travere Therapeutics, INC. | $47.04 | 2022-2023 | |
| Indivior INC. | $46.01 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $38.76 | 2021-2022 | |
| Baxter Healthcare | $38.36 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Itamar Medical INC | $32.57 | 2024 | Watchpatone |
| Otsuka America Pharmaceutical, INC. | $28.63 | 2023 | Jynarque |
| Amgen INC. | $28.43 | 2022 | |
| Daiichi Sankyo INC. | $19.57 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.65 | 2021 | |
| Janssen Biotech, INC. | $15.56 | 2021 | |
| Sun Pharmaceutical Industries INC. | $14.88 | 2021 | |
| Genzyme Corporation | $13.79 | 2021 | |
| Novo Nordisk INC | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mcelroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.